Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Combined sequence-based and genetic mapping analysis of complex traits in outbred rats.
Gateway to wellness: an occupational therapy collaboration with the national multiple sclerosis society.
Bupropion-Related Visual Hallucinations in a Veteran With Posttraumatic Stress Disorder and Multiple Sclerosis.
Stem cell therapy for central nerve system injuries: glial cells hold the key.
Vitamin D - immunomodulatory actions and new potentialities.
The pathogenic role of the inflammasome in neurodegenerative diseases.
The elusive biomarker for personalized medicine in multiple sclerosis: The search continues.
Shared HLA Class II in Six Autoimmune Diseases in Latin America: A Meta-Analysis.
Consequences of NMO-IgG binding to aquaporin-4 in neuromyelitis optica.
The cuprizone model: regional heterogeneity of pathology.
Acute transverse myelitis following Japanese encephalitis viral infection: an uncommon complication of a common disease.
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.
Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.
The discovery of natalizumab, a potent therapeutic for multiple sclerosis.
Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice.
The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a new class of nanomolar FKBP12 ligands.
An analytical model for estimating water exchange rate in white matter using diffusion MRI.
Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
The Immunomodulatory and Neuroprotective Effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): A Model of Multiple Sclerosis (MS).
Arterial, venous and other vascular risk factors in multiple sclerosis.
K(+) channel alterations in the progression of experimental autoimmune encephalomyelitis.
GeNeuro Announces the Launch of Phase IIb Proof-of-Concept Study with GNbAC1 in Multiple Sclerosis and Servier Equity Investment
A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design.
The grey matter correlates of impaired decision-making in multiple sclerosis.
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study.

Pages